Kathryn DiMarco
Fortuna: 516 792 $ al 31/05/2026
Fortuna: 516 792 $ al 31/05/2026
Ms. Kathryn DiMarco is a Senior Vice President-Finance & Controller at Organon & Co. Ms. DiMarco was previously employed as a Controller by Allergan Ltd. (Ireland) and an International Controller by Merck Sharp & Dohme Corp.
She received her undergraduate degree from Lehigh University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ORGANON & CO. 0,01 % | 31/03/2025 | 38.740 ( 0,01 % ) | 516 792 $ | 31/05/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| ORGANON & CO. | Comptroller/Controller/Auditor | 01/05/2025 |
| ALLERGAN PLC | Comptroller/Controller/Auditor | 01/01/2020 |
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Comptroller/Controller/Auditor | 01/01/2015 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Lehigh University
Lehigh University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Health Technology |
Allergan Ltd. (Ireland)
Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes pharmaceuticals, devices, biological, surgical & regenerative medicine products | Health Technology |
Organon & Co.
Organon & Co. Pharmaceuticals: MajorHealth Technology Develops and delivers women health, trusted legacy brands and therapeutics | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.